News | February 10, 2011

New Possibilities for UK Patients With Difficult-to-Treat Cancers

February 10, 2011 – For the first time in the UK, cancer patients are starting to receive treatment with Novalis Tx radiosurgery. This device, by Brainlab and Varian Medical Systems, gives the chance of a cure to those with inoperable tumors and offers the possibility to perform precise, painless treatment in a single patient visit.

The system makes it possible for doctors to treat patients with tumors virtually anywhere in the body in just a single session. Combining a 'sat nav' like targeting system and powerful treatment beams, it can destroy cancerous cells and helps to protect surrounding healthy tissue. Treatment is also made more patient-friendly by delivering frameless radiosurgery for brain tumors, an alternative to techniques that require immobilization with an invasive head ring that is affixed to the skull.

In its first year of operation at the brand new Clatterbridge Cancer Centre in Liverpool, it is expected to treat more than 800 cancer patients. It is estimated that 150 of these patients will be priority brain tumor patients where precise, non-invasive treatment is particularly effective.

"Unlike some other highly specialized radiation treatment machines, the Novalis Tx can treat many different types of cancer in all over the body allowing us to treat more cancer patients with a single device,” said Brian Haylock, consultant oncologist and clinical director for radiotherapy at Clatterbridge Centre for Oncology. “This coupled with the speed with which we can treat patients - in some cases in as little as 15 minutes in just one session - means the equipment will be available for the benefit of more patients here in the UK."

Later this year, Novalis Tx machines will become operational at two other specialist NHS cancer centers in Edinburgh and Manchester.

For more information:,

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...